

PHARMACY POLICY STATEMENT


	New policy for Omvoh created.
	Replaced TNfi trial with trial of two preferred biologics and added appendix.

References:

1. Omvoh [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2023.
2. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. 2019;114(3):384-413
3. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. 2020;158(5):1450-1461
4. Sands BE, Schreiber S, Blumenstein I, Chiorean MV, Ungaro RC, Rubin DT. Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis [published online ahead of print, 2023 Jul 12]. 2023;jjad112. doi:10.1093/ecco-jcc/jjad112
5. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. 2022;16(1):2-17. doi:10.1093/ecco-jcc/jjab178

Effective date: 04/01/2024

Revised date: 03/12/2024



<p>Approved for Psoriasis</p>	<ul style="list-style-type: none"> • Cosentyx • Enbrel • Preferred adalimumab product - adalimumab-adaz, adalimumab-fkjp, Hadlima, or Humira • Otezla • Skyrizi • Stelara • Tremfya
<p>Approved for Crohn's Disease</p>	<ul style="list-style-type: none"> • Preferred adalimumab product - adalimumab-adaz, adalimumab-fkjp, Hadlima, or Humira • Stelara
<p>Approved for Ulcerative Colitis</p>	<ul style="list-style-type: none"> • Preferred adalimumab product - adalimumab-adaz, adalimumab-fkjp, Hadlima, or Humira • Stelara • Rinvoq